1. Generics Bulletin

MSN Deals Out Of Movantik But Two ANDA Filers Remain

Indian Firm Bags Date-Certain Launch

 
• By Dean Rudge

India’s MSN Laboratories is set to move on a generic version of RedHill Biopharma’s Movantik (naloxegol oxalate) for opioid-induced constipation ahead of patent expiry under the terms of a patent-litigation settlement agreement.

Gavels
MSN has settled litigation with a number of plaintiffs with interest in the Movantik brand. • Source: Shutterstock

MSN Laboratories is set to launch a generic version of RedHill Biopharma’s Movantik (naloxegol oxalate) for opioid-induced constipation ahead of patent expiry after agreeing to settle patent-litigation proceedings with the Israel-based biotech and partners AstraZeneca and Nektar Therapeutics.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin